BR0006019A - Low adenosine antisense oligonucleotide, compositions, kit & method for treating airway disorders associated with bronchoconstriction, lung inflammation, allergy (s) & surfactant depletion - Google Patents

Low adenosine antisense oligonucleotide, compositions, kit & method for treating airway disorders associated with bronchoconstriction, lung inflammation, allergy (s) & surfactant depletion

Info

Publication number
BR0006019A
BR0006019A BR0006019-4A BR0006019A BR0006019A BR 0006019 A BR0006019 A BR 0006019A BR 0006019 A BR0006019 A BR 0006019A BR 0006019 A BR0006019 A BR 0006019A
Authority
BR
Brazil
Prior art keywords
adenosine
antisense
mrna
compositions
low
Prior art date
Application number
BR0006019-4A
Other languages
Portuguese (pt)
Inventor
Jonathan W Nyce
Original Assignee
Univ East Carolina
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ East Carolina filed Critical Univ East Carolina
Publication of BR0006019A publication Critical patent/BR0006019A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/18—Type of nucleic acid acting by a non-sequence specific mechanism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base

Abstract

Patente de Invenção: <B>"OLIGONUCLEOTìDEO DE ANTI-SENTIDO DE ADENOSINA BAIXO, COMPOSIçõES, KIT & MéTODO PARA TRATAMENTO DE DISTúRBIOS DE VIAS AéREAS ASSOCIADOS COM BRONCOCONSTRICçãO, INFLAMAçãO PULMONAR, ALERGIA(S) & DEPLEçãO DE SURFACTANTE"<D>. Um método in vivo de distribuir seletivamente um ácido nucleico a um gen alvo ou mRNA, compreende a administração local, por exemplo, ao sistema respiratório, de um sujeito de uma quantidade terapêutica de um oligonucleotídeo (oligo) que é de anti-sentido ao códon de iniciação, a região de codificação, as regiões de flanco genómicas da extremidade 5' e da extremidade 3', junções de <B>introneção<D> de 5' e 3' ou regiões dentro de 2 a 10 nucleotídeos das junções do gen, ou anti-sentido a um mRNA complementar ao gen em uma quantidade efetiva para alcançar o polinucleotídeo alvo e reduzindo ou inibindo expressão. Além disso um método para tratar um efeito mediado de adenosina, compreende administrando localmente a um sujeito um oligo de anti-sentido em uma quantidade efetiva para tratar a doença respiratória, pulmonar, ou de vias aéreas. A fim de minimizar disparando receptores de adenosina por seus metabolismos, os oligos administrados têm um conteúdo baixo de ou são essencialmente livres de adenosina. Uma composição e formulações farmacêuticas compreendem o anti-sentido de oligo a um receptor de adenosina, genes e mRNAs codificando-os, regiões de flanco genómica e mRNA, margens intron e exon e todos segmentos reguladores e funcionalmente relacionados dos gens e mRNAs codificando os polipeptídeos, seus sais e misturas. Várias formulações contém um transportador necessário, e optativamente outros aditivos e agentes ativos biologicamente. O agente de adenosina baixa ou livre de adenosina (des-A) para praticar o método da invenção pode ser preparado selecionando um(s) gen(s) alvo, região(s) de flanco genómica(s), RNA(s) e/ou polipeptídeo(s) associados(s) com uma(s) doença(s) ou condição(s) afligindo vias respiratórias pulmonares, obtendo a sequência do(s) RNA(s) correspondendo ao(s) gen(s) alvo e/ou região(s) de flanco genómica(s), e/ou RNAs codificando o(s) polipeptídeo(s) alvo, selecionando pelo menos um segmento do mRNA o qual pode ser até 60% livre de timidina (T) e sintetizando um ou mais oligo-nucleotídeo(s) de anti-sentido aos segmentos de mRNA os quais são livres de adenosina (A) substituindo uma base universal por A quando presente no oligonucleotídeo. O agente pode ser preparado por seleção de sequências de ácidos nucleicos alvos com estiramento de passagem de GC, os quais têm conteúdo T baixo, e optativamente substituindo A nos oligonucleotídeos de anti-sentido com uma "Base universal ou alternativa". Os agentes, composições e formulações são usados para profilaticamente, tratamento preventivo e terapêutico de enfermidades associadas com respiração prejudicada, alergia(s) pulmonar e/ou inflamação ou depleção de surfactante pulmonar ou hiproprodução de surfactante, tais como vasoconstricção, inflamação, alergias, rinite alérgica, asma, respiração impedida, dor pulmonar, fibrose cística, broncoconstricção. O presente tratamento é adequado para administração em combinação com outros tratamentos, por exemplo, antes, durante e após outros tratamentos, inluindo radiação, quimioterapia, terapia de anticorpo e cirurgia, entr outros, Alternativamente, o agente presente é efetivamente administrado profilaticamente ou terapeuticamente por si só para condições sem terapias conhecidas ou como um substituto para terapias exibindo efeitos colaterais indesejados. O tratamento desta invenção pode ser administrado diretamente no sistema respiratório de um sujeito de modo que o agente tenha acesso direto aos pulmões, ou por rotas efetivas de administração, por exemplo localmente, transdermicamente, por implantação, etc. em uma quantidade efetiva para reduzir ou inibir os sintomas da enfermidade.Invention Patent: <B> "LOW ADENOSINE ANTI-SENSE OLIGONUCLEOTYDE, COMPOSITIONS, KIT & METHOD FOR TREATING AIRWAY DISORDERS ASSOCIATED WITH BRONCOCONSTRUCTION, PULMONARY INFLAMMATION," ALPHAEOLOGY> ". An in vivo method of selectively delivering a nucleic acid to a target gene or mRNA, comprises local administration, for example, to the respiratory system, of a subject of a therapeutic amount of an oligonucleotide (oligo) that is antisense to the codon of initiation, the coding region, the genomic flank regions of the 5 'and 3' end, <B> 5 'and 3' <D> , or antisense to a mRNA complementary to the gene in an effective amount to reach the target polynucleotide and reduce or inhibit expression. In addition, a method for treating an adenosine-mediated effect, comprises administering a subject antisense oligo locally in an effective amount to treat respiratory, lung, or airway disease. In order to minimize triggering of adenosine receptors by their metabolisms, the administered oligos have a low content of or are essentially free of adenosine. A pharmaceutical composition and formulations comprise the oligo antisense to an adenosine receptor, genes and mRNAs encoding them, genomic and mRNA flank regions, intron and exon margins and all regulatory and functionally related segments of the genes and mRNAs encoding the polypeptides , its salts and mixtures. Various formulations contain a necessary carrier, and optionally other biologically active additives and agents. The low or adenosine adenosine (des-A) agent for practicing the method of the invention can be prepared by selecting a target gene (s), genomic flank region (s), RNA (s) and / or polypeptide (s) associated with a disease (s) or condition (s) afflicting pulmonary airways, obtaining the sequence of the RNA (s) corresponding to the target gene (s) and / or genomic flank region (s), and / or RNAs encoding the target polypeptide (s), selecting at least one segment of the mRNA which can be up to 60% free of thymidine (T) and synthesizing one or more antisense oligo-nucleotide (s) to the mRNA segments which are free of adenosine (A) replacing a universal base with A when present in the oligonucleotide. The agent can be prepared by selecting target nucleic acid sequences with GC pass stretch, which have low T content, and optionally substituting A in the antisense oligonucleotides with a "Universal or alternative base". Agents, compositions and formulations are used for prophylactically, preventive and therapeutic treatment of diseases associated with impaired breathing, pulmonary allergy (s) and / or inflammation or depletion of pulmonary surfactant or hypo-production of surfactant, such as vasoconstriction, inflammation, allergies, rhinitis allergic, asthma, shortness of breath, lung pain, cystic fibrosis, bronchoconstriction. The present treatment is suitable for administration in combination with other treatments, for example, before, during and after other treatments, including radiation, chemotherapy, antibody therapy and surgery, among others. Alternatively, the present agent is effectively administered prophylactically or therapeutically by itself for conditions without known therapies or as a substitute for therapies exhibiting unwanted side effects. The treatment of this invention can be administered directly to a subject's respiratory system so that the agent has direct access to the lungs, or by effective routes of administration, for example locally, transdermally, by implantation, etc. in an effective amount to reduce or inhibit the symptoms of the disease.

BR0006019-4A 1999-04-06 2000-03-24 Low adenosine antisense oligonucleotide, compositions, kit & method for treating airway disorders associated with bronchoconstriction, lung inflammation, allergy (s) & surfactant depletion BR0006019A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12795899P 1999-04-06 1999-04-06
PCT/US2000/008020 WO2000062736A2 (en) 1999-04-06 2000-03-24 Low adenosine anti-sense oligonucleotide, compositions, kit and method for treatment of airway disorders associated with bronchoconstriction, lung inflammation, allergy(ies) and surfactant depletion

Publications (1)

Publication Number Publication Date
BR0006019A true BR0006019A (en) 2001-03-13

Family

ID=22432865

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0006019-4A BR0006019A (en) 1999-04-06 2000-03-24 Low adenosine antisense oligonucleotide, compositions, kit & method for treating airway disorders associated with bronchoconstriction, lung inflammation, allergy (s) & surfactant depletion

Country Status (9)

Country Link
EP (1) EP1168919A4 (en)
JP (1) JP2003515525A (en)
CN (1) CN1330513A (en)
AU (1) AU4031700A (en)
BR (1) BR0006019A (en)
CA (1) CA2330022A1 (en)
HK (1) HK1042017A1 (en)
IL (1) IL140054A0 (en)
WO (1) WO2000062736A2 (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6737040B1 (en) 1998-08-04 2004-05-18 Diadexus, Inc. Method and antibody for imaging breast cancer
US6730477B1 (en) 1998-08-04 2004-05-04 Diadexus, Inc. Method of diagnosing, monitoring and staging breast cancer
JP2002539831A (en) * 1999-03-26 2002-11-26 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド 47 human secreted proteins
DE10049549A1 (en) * 2000-10-06 2002-05-02 Markus Hecker Inhibitor of the transcription factor IFR-1, useful for treating e.g. transplant rejection and autoimmune disease, reduces expression of CD40
CA2451738C (en) 2001-07-06 2013-09-17 Topigen Pharmaceutique Inc. Methods for increasing in vivo efficacy of oligonucleotides and inhibiting inflammation in mammals using 2-amino-2'-deoxyadenosine
WO2004086052A2 (en) * 2003-03-28 2004-10-07 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g-protein-coupled receptor adenosine a2b (adora2b)
US7671182B2 (en) * 2003-03-31 2010-03-02 Council Of Scientific & Industrial Research Gene variants of signal transducer and activator of transcription-6 (STAT 6) variants and process of detection the same
JP5838017B2 (en) * 2003-12-03 2015-12-24 コーダ セラピューティクス， インコーポレイテッド Antisense compounds targeted against connexins and methods of use thereof
WO2006010492A1 (en) * 2004-07-28 2006-02-02 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with tryptase 1 (tps1)
US8673268B2 (en) 2004-10-15 2014-03-18 Galapagos N.V. Molecular targets and compounds, and methods to identify the same, useful in the treatment of joint degenerative and inflammatory diseases
US7485468B2 (en) 2004-10-15 2009-02-03 Galapagos Bv Molecular targets and compounds, and methods to identify the same, useful in the treatment of joint degenerative and inflammatory diseases
US8765700B2 (en) 2004-10-20 2014-07-01 Antisense Therapeutics Ltd. Topical administrations of antisense compounds to VLA-4 for the treatment of respiratory conditions
WO2006045202A1 (en) 2004-10-29 2006-05-04 Topigen Pharmaceuticals Inc. Antisense oligonucleotides for treating allergy and neoplastic cell proliferation
CA2587903A1 (en) 2004-11-17 2006-05-26 Amgen Fremont Inc. Fully human monoclonal antibodies to il-13
WO2006107826A2 (en) 2005-04-04 2006-10-12 The Board Of Regents Of The University Of Texas System Micro-rna's that regulate muscle cells
JP2010500360A (en) * 2006-08-10 2010-01-07 アルボア コーポレーション Local therapy of lower respiratory inflammatory diseases with inflammatory cytokine inhibitors
JP2012521766A (en) * 2009-03-27 2012-09-20 メルク・シャープ・エンド・ドーム・コーポレイション RNA interference-mediated inhibition of high affinity IgE receptor α chain (FCεR1α) gene expression using small interfering nucleic acids (siNA)
JP6590790B2 (en) * 2013-04-19 2019-10-16 エピオンティス ゲーエムベーハー Method for identifying quantitative cellular composition in biological samples
CN112969799A (en) * 2018-09-26 2021-06-15 奥姆生命科技公司 2' FANA modified FOXP3 antisense oligonucleotides and methods of use thereof
CN109260217A (en) * 2018-09-30 2019-01-25 深圳松乐生物科技有限公司 3`- deoxyinosine nucleosides is in preparation for the application in a variety of disease drugs, food or health care product
CN114591963B (en) * 2022-05-10 2022-07-19 上海优替济生生物医药有限公司 sgRNA and method for constructing GM-CSF (-) cell by using same

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993010820A1 (en) * 1991-11-26 1993-06-10 Gilead Sciences, Inc. Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines
US5858784A (en) * 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
US5320962A (en) * 1992-07-22 1994-06-14 Duke University DNA encoding the human A1 adenosine receptor
US5801154A (en) * 1993-10-18 1998-09-01 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of multidrug resistance-associated protein
US6025339A (en) * 1995-06-07 2000-02-15 East Carolina University Composition, kit and method for treatment of disorders associated with bronchoconstriction and lung inflammation
US6040296A (en) * 1995-06-07 2000-03-21 East Carolina University Specific antisense oligonucleotide composition & method for treatment of disorders associated with bronchoconstriction and lung inflammation
US5994315A (en) * 1995-06-07 1999-11-30 East Carolina University Low adenosine agent, composition, kit and method for treatment of airway disease
CN1202900A (en) * 1995-11-21 1998-12-23 Icn药品公司 Inhibition of tumor growth by antisense oligonucleotides for IL-8 and Il-8 receptor
US5856462A (en) * 1996-09-10 1999-01-05 Hybridon Incorporated Oligonucleotides having modified CpG dinucleosides
JP4663113B2 (en) * 1997-09-05 2011-03-30 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Use of immunostimulatory oligonucleotides to prevent or reduce antigen-stimulated granulocyte-mediated inflammation
WO1999060166A1 (en) * 1998-05-21 1999-11-25 Isis Pharmaceuticals, Inc. Compositions and methods for the pulmonary delivery of nucleic acids
AU5337499A (en) * 1998-08-03 2000-03-06 East Carolina University Low adenosine anti-sense oligonucleotide agent, composition, kit and treatments

Also Published As

Publication number Publication date
CA2330022A1 (en) 2000-10-26
JP2003515525A (en) 2003-05-07
EP1168919A4 (en) 2002-03-06
WO2000062736A2 (en) 2000-10-26
EP1168919A2 (en) 2002-01-09
CN1330513A (en) 2002-01-09
AU4031700A (en) 2000-11-02
IL140054A0 (en) 2002-02-10
HK1042017A1 (en) 2002-08-02
WO2000062736A3 (en) 2001-10-11

Similar Documents

Publication Publication Date Title
BR0006019A (en) Low adenosine antisense oligonucleotide, compositions, kit &amp; method for treating airway disorders associated with bronchoconstriction, lung inflammation, allergy (s) &amp; surfactant depletion
Hirano et al. Acute quadriplegic myopathy: a complication of treatment with steroids, nondepolarizing blocking agents, or both
JP2505944B2 (en) Pharmaceutical composition for treating asthma containing (S) -α-fluoromethyl-histidine and its ester
WO2002085308A3 (en) Antisense and anti-inflammatory based compositions to treat respiratory disorders
US20120052077A1 (en) Therapeutic modulation of vaginal epithelium boundary lubrication
JP2015518713A (en) Compositions and methods for modulating UTRN expression
JP2015523853A (en) Compositions and methods for modulating ATP2A2 expression
JP2015523854A (en) Compositions and methods for modulating SMN gene family expression
JP2015518711A (en) Compositions and methods for modulating BDNF expression
JP2015518710A (en) Compositions and methods for regulating hemoglobin gene family expression
EP3033425A1 (en) Compositions and methods for modulating expression of frataxin
HU227519B1 (en) Synergic pharmaceutical composition containing combination of formoterol and budesonide
JP2011507857A5 (en)
WO1999063938A9 (en) Composition and method for prevention and treatment of cardiopulmonary and renal failure or damage associated with ischemia, endotoxin release, ards or brought about by administration of certain drugs
WO2000009525A3 (en) Low adenosine anti-sense oligonucleotide agent, composition, kit and treatments
US20130197069A1 (en) Methods for treating stress induced emotional disorders
Tian et al. Effects of Bufei Yishen granules combined with acupoint sticking therapy on pulmonary surfactant proteins in chronic obstructive pulmonary disease rats
US8877740B2 (en) Compound composition for inhalation used for treating asthma
ES2206706T3 (en) USE OF DEHYDRO-EPIANDROSTERONE AND AN AROMATASE INHIBITING AGENT FOR THE PREPARATION OF A MEDICINAL PRODUCT FOR THE TREATMENT OF A RELATIVE AND ABSOLUTE DEFECT OF ANDROGENS IN A VARON.
KR20060011783A (en) Composition, formulations and kit for treatment of respiratory and lung disease with dehydroepi androsterone(s) steroid and an anti-muscarinic agent(s)
Itoh et al. Clinical study on the psychotropic effects of caerulein an open clinical trial in chronic schizophrenic patients
JP5068912B2 (en) Novel combination of loteprednol and β2 adrenergic receptor agonist
Jones A new estrogen receptor antagonist–an overview of available data
BR0317132A (en) Methods of diagnosis and treatment of interstitial lung disease
US10059948B2 (en) Antisense treatment of radiation induced diseases in the gastrointestinal tract

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A, 6A, 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1929 DE 26/12/2007.